Zevra Therapeutics Inc ZVRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
-
Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
-
ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA)
-
ZVRA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zevra Therapeutics
-
ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law
-
Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA)
Trading Information
- Previous Close Price
- $11.32
- Day Range
- $10.53–11.25
- 52-Week Range
- $8.02–15.03
- Bid/Ask
- $10.53 / $10.56
- Shares Outstanding
- 59.38M
- Market Cap
- $628.28M
- Volume/Avg
- 308,933 / 1M
Key Statistics
- Price/Earnings (Normalized)
- 10.47
- Price/Sales
- 4.96
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 61
- Website
- https://www.zevra.com
Valuation
|
Metric
|
ZVRA
|
|---|---|
Price/Earnings (Normalized) | 10.47 |
Price/Book Value | 3.09 |
Price/Sales | 4.96 |
Price/Cash Flow | 18.18 |
Price/Earnings
ZVRA
Financial Strength
|
Metric
|
ZVRA
|
|---|---|
Quick Ratio | 5.02 |
Current Ratio | 5.17 |
Interest Coverage | 11.35 |
Quick Ratio
ZVRA
Profitability
|
Metric
|
ZVRA
|
|---|---|
Return on Assets (Normalized) | 16.99% |
Return on Equity (Normalized) | 28.56% |
Return on Invested Capital (Normalized) | 21.37% |
Return on Assets
ZVRA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|sLSS!% | LOCK|>$tGK | $129B | |||
| Moderna Inc
MRNA
| LOCK|^JxYgL> | LOCK|l^ | $85B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^cx%PM | LOCK|sTRX | $79B | |||
| argenx SE ADR
ARGX
| LOCK|ZTlRzpj | LOCK|^^ | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?^HX@K | LOCK|J<< | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^rrPBkw | LOCK|h!M&S | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@?l@%<F | LOCK|Fx@dD | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|?d@Q#m | LOCK|X# | $24B | |||
| Incyte Corp
INCY
| LOCK|jw@!%bb | LOCK|>@b | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|^!pbHvF | LOCK|k< | $14B |
United States